Abstract
Artificial Intelligence (AI) has a multitude of applications in cancer research and oncology. However, the training of AI systems is impeded by the limited availability of large datasets due to data protection requirements and other regulatory obstacles. Federated and swarm learning represent possible solutions to this problem by collaboratively training AI models while avoiding data transfer. However, in these decentralized methods, weight updates are still transferred to the aggregation server for merging the models. This leaves the possibility for a breach of data privacy, for example by model inversion or membership inference attacks by untrusted servers. Homomorphically encrypted federated learning (HEFL) is a solution to this problem because only encrypted weights are transferred, and model updates are performed in the encrypted space. Here, we demonstrate the first successful implementation of HEFL in a range of clinically relevant tasks in cancer image analysis on multicentric datasets in radiology and histopathology. We show that HEFL enables the training of AI models which outperform locally trained models and perform on par with models which are centrally trained. In the future, HEFL can enable multiple institutions to co-train AI models without forsaking data governance and without ever transmitting any decryptable data to untrusted servers.
One Sentence Summary Federated learning with homomorphic encryption enables multiple parties to securely co-train artificial intelligence models in pathology and radiology, reaching state-of-the-art performance with privacy guarantees.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
JNK is supported by the German Federal Ministry of Health (DEEP LIVER, ZMVI1-2520DAT111) and the Max-Eder-Programme of the German Cancer Aid (grant #70113864). The DACHS study (H.B., J.C.-C. and M.H.) was supported by the German Research Council (BR 1704/6-1, BR 1704/6-3, BR 1704/6-4, CH 117/1-1, HO 5117/2-1, HO 5117/2-2, HE 5998/2-1, HE 5998/2-2, KL 2354/3-1, KL 2354/3-2, RO 2270/8-1, RO 2270/8-2, BR 1704/17-1 and BR 1704/17-2), the Interdisciplinary Research Program of the National Center for Tumor Diseases (NCT; Germany) and the German Federal Ministry of Education and Research (01KH0404, 01ER0814, 01ER0815, 01ER1505A and 01ER1505B). The Epi700 creation was enabled by funding from Cancer Research UK (C37703/A15333 and C50104/A17592) and a Northern Ireland HSC R&D Doctoral Research Fellowship (EAT/4905/13). P.Q. and N.P.W. are supported by Yorkshire Cancer Research Programme grants L386 (QUASAR series) and L394 (YCR BCIP series). P.Q. is a National Institute of Health Research senior investigator. J.A.J. has received funds from Health and Social Care Research and Development (HSC R&D) Division of the Public Health Agency in Northern Ireland (R4528CNR and R4732CNR) and the Friends of the Cancer Centre (R2641CNR) for development of the Northern Ireland Biobank.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was carried out in accordance with the Declaration of Helsinki. This study is a retrospective analysis of publicly available anonymized MRI examinations and of anonymized histopathological tissue samples from multiple cohorts of cancer patients. Collection and anonymization of patients in all cohorts took place in each contributing center. Approval by the local ethics committee at each contributing center was given if applicable (QUASAR: North East York Research Ethics Committee; YCR: Ethical approval was not required, because screening was recommended in all patients diagnosed with CRC. Testing was considered part of the standard of care clinical pathway; Epi700: Northern Ireland Biobank (NIB13/0069, NIB13/0087, NIB13/0088 and NIB15/0168), DACHS: Ethics committee of the Medical Faculty, University of Heidelberg). Approval of the ethics committee at the University Hospital of Aachen to carry out the study was given under reference number Ethikkommission EK 259/22.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are in part publicly available, in part proprietary datasets provided under collaboration agreements. Data from the BraTS collective is publicly available under https://www.med.upenn.edu/cbica/brats2020/data.html. Data (including histological images) from the TCGA database are available at https://portal.gdc.cancer.gov/. All molecular data for patients in the TCGA cohorts are available at https://cbioportal.org. Data access for the Northern Ireland Biobank can be requested at http://www.nibiobank.org/for-researchers. All other data can be requested from the respective study groups who independently manage data access for their study cohorts.
